Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

@article{Chen2017PhaseIS,
  title={Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.},
  author={Robert W. Chen and Pier Luigi Zinzani and Michelle A Fanale and Philippe F Armand and Nathalie A. Johnson and Pauline Brice and John Radford and Vincent Ribrag and Daniel Molin and Theodoros Vassilakopoulos and Akihiro Tomita and Bastian von Tresckow and Margaret A Shipp and Yinghua Zhang and Alejandro D. Ricart and Arun Balakumaran and Craig H. Moskowitz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 19},
  pages={2125-2132}
}
Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 40 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Checkpoint inhibition in lymphoma.

Clinical advances in hematology & oncology : H&O • 2018

Similar Papers

Loading similar papers…